Incyte Ready To Go For Approval Of Topical Ruxolitinib In Atopic Dermatitis
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.
You may also be interested in...
Six of seven mid-sized companies enjoyed valuation increases over the first quarter, with four firms up by 7.5% or more. Some are benefiting from direct involvement in addressing the COVID-19 pandemic.
Deal Snapshot: Forte finds a route to the public markets to support moving its atopic dermatitis drug into Phase II; most of Tocagen’s assets will be sold off.
The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.